Portable Continuous Positive Airways Pressure (CPAP) in Excessive Central Airway Collapse (ECAC) Study
Sponsored by Papworth Hospital NHS Foundation Trust
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 10 months ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
1. Diagnosis of ECAC based on >50% reduction of the antero-posterior diameter of large airways demonstrated on dynamic CT thorax or bronchoscopy. Only patients with tracheal and/or bilateral large bronchi (main to lobar) involvement will be included.
2. Symptoms of dyspnoea felt to be predominantly caused by ECAC (where ECAC is the only respiratory pathology or dyspnoea is clearly out of proportion to a co-morbid respiratory condition)
3. Medical Research Council (MRC) breathlessness scale of 3 (I stop for breath after walking about 100 yards or after a few minutes on level ground) or more.
4. Age over 18 years
5. Able to give informed consent -
Exclusion Criteria
- Patients with dynamic collapse of only segmental airways
- Comorbidity which is likely to be an additional limiting factor in exercise tolerance
- Contraindication to CPAP
- Contraindication to incremental shuttle walk testing (ISWT), including; myocardial infarction within the last 3-5 days, unstable angina, uncontrolled arrhythmia, severe symptomatic cardiac or valvular disease, acute pulmonary embolus, uncontrolled asthma, syncope, mental impairment resulting in inability to perform test.
- Resting oxygen saturations <90% on air or need for ambulatory oxygen therapy
- Immobility that would make ISWT unfeasible
- Severe emphysema
- Acute infectious disease
- Acute respiratory illness